Hennion & Walsh Asset Management Inc. Has $4.70 Million Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Hennion & Walsh Asset Management Inc. boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 40.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 289,279 shares of the company’s stock after buying an additional 83,117 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $4,701,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of TEVA. New Covenant Trust Company N.A. acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $28,000. EntryPoint Capital LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $30,000. Beach Investment Counsel Inc. PA acquired a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $48,000. Industrial Alliance Investment Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $54,000. Finally, GAMMA Investing LLC increased its position in shares of Teva Pharmaceutical Industries by 105.7% during the 2nd quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock worth $55,000 after purchasing an additional 1,741 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 519,000 shares of the business’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total value of $8,838,570.00. Following the completion of the sale, the director now directly owns 981,000 shares in the company, valued at approximately $16,706,430. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares of the company’s stock, valued at approximately $777,285. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Roberto Mignone sold 519,000 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total value of $8,838,570.00. Following the completion of the transaction, the director now directly owns 981,000 shares of the company’s stock, valued at $16,706,430. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Stock Performance

TEVA traded down $0.01 during trading on Monday, hitting $18.25. The stock had a trading volume of 4,914,866 shares, compared to its average volume of 10,320,007. The company has a 50 day moving average price of $16.91 and a 200-day moving average price of $15.16. The firm has a market cap of $20.67 billion, a price-to-earnings ratio of -44.54, a P/E/G ratio of 1.57 and a beta of 0.90. Teva Pharmaceutical Industries Limited has a one year low of $8.06 and a one year high of $18.58. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TEVA. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 3rd. UBS Group boosted their price target on Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, July 10th. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Wednesday, July 10th. Piper Sandler reiterated an “overweight” rating and set a $20.00 target price (up from $19.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, May 13th. Finally, Jefferies Financial Group lifted their target price on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $18.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.